In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

To make it easier for children with asthma to receive care at school, a new study will assess the impact of making the ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Platform-specific achievement systems transformed an isolated gameplay preference into a visible, competitive subculture. What emerged wasn’t just a playstyle but an ecosystem of tracking tools, ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

BD (NYSE: BDX) today announced the first Phasix hernia mesh laparotomy reinforcement case performed in Greece.

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Artificial sweeteners have long been cast as either miracle weight-loss allies or metabolic saboteurs — but the science is ...

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

Regardless of whether you are just dipping your toes into board games or are a long-time fan looking for a big, crunchy match ...